Polyrizon Ltd
Research Polyrizon Ltd (PLRZ) on Bullrun: market cap USD 9.36M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPLRZ
- ExchangeNASDAQ
- CountryIsrael
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 9.36M
- Financial periodFY2025
- RevenueUSD 0
- Net income-USD 3.34M
- Free cash flow-USD 4.54M
Valuation Snapshot
latest market cap is USD 9.36M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 3.34M | -USD 4.54M | n/a | 4.9 | USD 1.31M | n/a | USD 20.99M |
| FY2024 | USD 0 | -USD 1.55M | -USD 1.15M | n/a | 805.2 | USD 2.55M | USD 151.00K | USD 5.29M |
| FY2023 | USD 0 | -USD 600.00K | -USD 537.00K | n/a | 494.4 | USD 4.00K | USD 200.00K | -USD 191.00K |
| FY2022 | USD 0 | -USD 779.00K | -USD 1.14M | n/a | 0.6 | USD 36.00K | USD 622.00K | -USD 900.00K |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 9.36M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 8.84M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 9.11M | n/a | n/a | n/a |
About Polyrizon Ltd
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; and PL-16 for influenza blockers. Polyrizon Ltd.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Polyrizon Ltd's market cap?
Polyrizon Ltd's market capitalization is USD 9.36M.
What does Polyrizon Ltd do?
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.